Waters to open analytical lab in UK biohub

By .

- Last updated on GMT

Former AstraZeneca R&D site in Alderly Park, Cheshire, is now  home to over 100,000 sq m of scientific laboratory space
Former AstraZeneca R&D site in Alderly Park, Cheshire, is now home to over 100,000 sq m of scientific laboratory space

Related tags: High performance liquid chromatography, Chromatography

Waters Corporation will offer an open access analytical laboratory and technology support  to biotechs based at a former AstraZeneca site in the UK.

Alderly Park, near Manchester, UK, was sold off by AstraZeneca to Machester Science Parks – a public-private partnership – in 2014​, and yesterday analytical equipment and technology firm Waters announced it has struck an agreement to launch an open access analytical laboratory there.

“This laboratory is a dedicated Open Access Laboratory, for the benefit of all companies located in the BioHub at Alderley Park [known as BioCity],”​ company spokesman Chris Orlando told this publication.

“Scientists on the site will gain access to cutting edge Waters capabilities through the Open Access facility which will be managed and run by BioCity, on a fee-for-sample/time/service basis. Support on the use of the facility, and the technology available, will be provided by an experienced laboratory manager.”

The firm already has its mass spectrometry headquarters and demonstration laboratory in nearby Wilmslow, but this new facility will focus on providing “cost-effective access to the kinds of cutting edge analytical technologies which underpin modern life and health sciences research,”​ he continued.

“Many, if not all, the companies at BioHub are engaged in cutting edge, and diverse, research and development. Close engagement with companies using the facility will give Waters a deeper insight into their needs and challenges.”

The firm’s Ultra Performance Liquid Chromatography (UPLC) systems, mass spectrometry (MS) and informatics technologies will be available at the new laboratory when it opens early this year, as will a nuclear magnetic resonance (NMR) system provided by Manchester Science Partnerships.

Related news

Show more

Related products

show more

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Related suppliers

Follow us


View more